Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment and Evaluation of Endocannabinoid System Activity

Status unknownNot a drug-phase studyRelapsing and progressiveNCT02331654

What it found

Paper found, not read

A paper reports the results; we have not read it yet. See Papers below.

What was tested

Treatment tested

  • Experimental treatment

Placebo

  • Placebo treatment

What it measured

Main measures

  • sDCS efficacy in pain as determined by NPSI and NRS scale

    30 days

    Pain

Other measures (2)

  • Central endocannabinoid level as determined by Activity of Fatty Acid Amide Hydrolase (FAAH) in platelets

    30 days

    SpasticityBladder, bowel and sexual functionPain
  • Spasticity as determined by Ashworth Scale

    30 days

    Nerve conduction testsSpasticity

Who could take part

Relapsing and progressive · 18 and over

Show the full criteria

Inclusion criteria

* Relapsing-remitting (RR), secondary-progressive (SP) and primary-progressive (PP) MS patients, affected by neuropathic or nociceptive chronic pain conditions in accordance to 1994 IASP (International Association for the Study of Pain) classification

Exclusion criteria

* Any form of headache * Cognitive impairment (Minimental State Examination \<= 21) * Psychiatry diseases, in particular depression (Back Depression Inventory Scale >15)

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

Pain represents one of the most common symptoms of Multiple Sclerosis (MS) that can seriously affect patient health-related quality of life. Central neuropathic pain, the main form of pain in MS patients, represents a significant clinical problem, in consideration of its poorly responsiveness to available therapies. Direct Current Stimulation (tDCS) is a non-invasive, well-tolerated procedure with an high and well documented neuromodulation activity at Central Nervous System (CNS) level. First evidences obtained by animal, neurophysiological and clinical studies suggested its potential efficacy in neuropathic pain treatment. In particular spinal DCS (sDCS) has been proven to modulate Nociceptive Withdrawal Reflex (NWR), an objective and sensitive tool to explore pain processing at the Spinal Level and recommended by European Federation of Neurological Society (EFNS) to evaluate the analgesic effect of treatments. In this order of view the investigators' objective is to investigate sDCS efficacy in MS neurophatic pain treatment applying validated clinical scales, neurophysiological acquisitions and specific biological marker dosages.

Papers

Loading reviews and guidelines…

History

    1. Started

      Nov 2013

    2. Main results due

      Jun 2015

    3. Finished

      Feb 2016

    Assembled by software from public sources.